Principal Financial Group Inc. lowered its position in shares of Stryker Corporation (NYSE:SYK) by 0.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 472,008 shares of the medical technology company’s stock after selling 824 shares during the quarter. Principal Financial Group Inc. owned 0.13% of Stryker Corporation worth $67,034,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of SYK. Wellington Management Group LLP grew its holdings in Stryker Corporation by 0.5% during the first quarter. Wellington Management Group LLP now owns 4,569,118 shares of the medical technology company’s stock valued at $601,525,000 after purchasing an additional 24,139 shares during the period. Stratos Wealth Partners LTD. boosted its holdings in shares of Stryker Corporation by 13.8% in the first quarter. Stratos Wealth Partners LTD. now owns 4,147 shares of the medical technology company’s stock valued at $546,000 after buying an additional 503 shares during the period. Lakeview Capital Partners LLC acquired a new position in shares of Stryker Corporation in the first quarter valued at approximately $211,000. Teachers Advisors LLC boosted its holdings in shares of Stryker Corporation by 5.9% in the first quarter. Teachers Advisors LLC now owns 399,505 shares of the medical technology company’s stock valued at $52,595,000 after buying an additional 22,169 shares during the period. Finally, Boston Financial Mangement LLC boosted its holdings in shares of Stryker Corporation by 1.0% in the first quarter. Boston Financial Mangement LLC now owns 33,952 shares of the medical technology company’s stock valued at $4,470,000 after buying an additional 335 shares during the period. Hedge funds and other institutional investors own 74.15% of the company’s stock.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is owned by corporate insiders.
Stryker Corporation (NYSE SYK) opened at $155.75 on Tuesday. The firm has a market cap of $57,812.22, a PE ratio of 24.48, a PEG ratio of 2.43 and a beta of 0.79. Stryker Corporation has a 1 year low of $106.48 and a 1 year high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The company’s revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.39 earnings per share. sell-side analysts predict that Stryker Corporation will post 6.47 EPS for the current fiscal year.
Several research analysts have recently weighed in on SYK shares. Wells Fargo & Company upped their price target on shares of Stryker Corporation from $160.00 to $166.00 in a report on Friday, October 27th. Cowen and Company reiterated a “buy” rating and issued a $160.00 price target (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Stifel Nicolaus upped their price target on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a report on Friday, July 28th. Zacks Investment Research upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target for the company in a report on Monday, July 17th. Finally, BidaskClub upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have assigned a buy rating to the company. Stryker Corporation currently has an average rating of “Hold” and a consensus price target of $151.52.
TRADEMARK VIOLATION WARNING: This report was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/11/14/principal-financial-group-inc-has-67-03-million-position-in-stryker-corporation-syk.html.
Stryker Corporation Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.